Axitinib: Optimizando el tratamiento de segunda línea del cáncer renal - page 14

AXIS: phase III study design with axitinib
• First phase III head to head st d s a targeted agent in second line mRCC, ‐ ‐ u y v ‐
Axitinib
R
A
N
Eligibility:
5 mg BID*
(n=361)
1 1
D
O
M
I
ƒ mRCC clear‐cell histology
ƒ Failure of one first‐line regimen
containing:
S iti ib
Sorafenib
400 mg BID
:
N=723 S
A
T
I
‒ un n
‒ Bevacizumab + IFN‐α
‒ Temsirolimus, or
‒ Cytokines
ƒ Stratification by prior regimen and (n=362)
O
N
ECOG PS
Primary endpoint: PFS
Rini et al. Lancet 2011